Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nexalin Technology, Inc. (NXL : NSDQ)
 
 • Company Description   
Nexalin Technology Inc. designs and develops neurostimulation products for mental health epidemic. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. Nexalin Technology Inc. is based in Houston, Texas.

Number of Employees: 8

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.38 Daily Weekly Monthly
20 Day Moving Average: 246,174 shares
Shares Outstanding: 20.58 (millions)
Market Capitalization: $7.77 (millions)
Beta: 3.56
52 Week High: $2.00
52 Week Low: $0.31
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -12.39% -16.67%
12 Week -27.64% -33.11%
Year To Date -32.31% -34.26%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1776 YORKTOWN SUITE 550
-
Houston,TX 77056
USA
ph: 832-260-0222
fax: -
nxl@crescendo-ir.com http://www.nexalin.com
 
 • General Corporate Information   
Officers
Mark White - Chief Executive Officer
Justin Van Fleet - Chief Financial Officer
Leslie Bernhard - Director
Alan Kazden - Director
David Owens - Director

Peer Information
Nexalin Technology, Inc. (EVOL)
Nexalin Technology, Inc. (RAMP)
Nexalin Technology, Inc. (EFOR)
Nexalin Technology, Inc. (LGTY)
Nexalin Technology, Inc. (ALOT)
Nexalin Technology, Inc. (CXT)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Technology Services
Sector: Business Services
CUSIP: 65345B201
SIC: 3845
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/05/26
Share - Related Items
Shares Outstanding: 20.58
Most Recent Split Date: (:1)
Beta: 3.56
Market Capitalization: $7.77 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.69
Price/Cash Flow: -
Price / Sales: 28.17
EPS Growth
vs. Year Ago Period: 26.67%
vs. Previous Quarter: 15.38%
Sales Growth
vs. Year Ago Period: -63.41%
vs. Previous Quarter: -91.28%
ROE
03/31/26 - -191.88
12/31/25 - -195.69
09/30/25 - -207.46
ROA
03/31/26 - -166.43
12/31/25 - -171.05
09/30/25 - -184.51
Current Ratio
03/31/26 - 4.07
12/31/25 - 4.85
09/30/25 - 13.45
Quick Ratio
03/31/26 - 3.85
12/31/25 - 4.70
09/30/25 - 13.01
Operating Margin
03/31/26 - -3,018.12
12/31/25 - -2,722.19
09/30/25 - -5,527.39
Net Margin
03/31/26 - -3,018.12
12/31/25 - -2,722.19
09/30/25 - -5,527.39
Pre-Tax Margin
03/31/26 - -3,018.48
12/31/25 - -2,722.19
09/30/25 - -5,527.39
Book Value
03/31/26 - 0.14
12/31/25 - 0.20
09/30/25 - 0.27
Inventory Turnover
03/31/26 - 0.31
12/31/25 - 0.38
09/30/25 - 0.28
Debt-to-Equity
03/31/26 - 0.00
12/31/25 - 0.00
09/30/25 - 0.00
Debt-to-Capital
03/31/26 - 0.00
12/31/25 - 0.00
09/30/25 - 0.00
 

Powered by Zacks Investment Research ©